Sareum Holdings plc

Climate Impact & Sustainability Data (2021, 2022, 2023)

Short-term Goals:

Submit a CTA for first-in-human studies with SDC-1801 in mid-2022, aiming to commence clinical studies later in the year.

Covid-19 pandemic impacted the Company’s network of Contract Research Organisations, increasing lead times for new experiments and causing delays to final preclinical studies for SDC-1801 before CTA filing.

The Directors do not expect the ongoing pandemic to significantly impact the operations of the Group.

All employees have been trained on anti-bribery, corruption and whistle blowing procedures.

Short-term Goals:

initiate clinical trials for SDC-1801 to provide critical safety and dosing information, with a planned trial in psoriasis patients in 2023

Supply chain issues and labor shortages remain, and could impact on development timelines.
the drug discovery programmes undertaken may fail due to fundamental scientific uncertainty
the Group may not complete sufficient commercial partnerships to create a sustainable business
it may not be possible to raise sufficient funding to support the Group through to sustained profitability

The Group’s low cost base ensures that funds are used in the most efficient way.
We undertake extensive early research and create a dossier of information that enables us and our advisers to evaluate the potential of a candidate before we seek to progress to preclinical or clinical phases.
We also seek collaboration partners whose own due diligence reaffirms our assessment of a candidate’s potential.
We work closely with our partners to anticipate and plan around any likely delays.
Collaboration contracts clearly outline responsibilities and key milestones as well as cost, licensing and revenue sharing.
The management and advisory boards gather as much information as possible on competitive products and programmes.
Progress and key milestones are monitored to understand how these may affect our own programmes.
Sareum also pursues more than one development programme in order to mitigate the overall risk to the Group.
The Directors address these uncertainties by reviewing reports on scientific progress, business development and financial status at the monthly Board meetings and implementing alternative plans to reduce the risks if these are considered necessary.

All employees have been trained on anti-bribery, corruption and whistle blowing procedures

Medium-term Goals:

Subject to satisfactory safety, additional funding and relevant regulatory and recruitment preparations, we plan to commence a Phase 1b trial of SDC-1801 in psoriasis patients shortly thereafter, with a readout from this part of the study expected by the end of 2024.

Short-term Goals:

Initial safety data from the Phase 1a trial are expected to be available in 1H 2024.

The principal financial risks are the ability to raise sufficient funds to support the Company through to profitability and failure to secure licensing agreements.
There are a number of risks in developing drug candidates due to a long and complex development process.
Our ability to stop others exploiting our intellectual property, without first obtaining a licence, is critical to our long-term success.
Working with third parties carries a risk of loss of control on progress and can lead to research delays.
There always remains the possibility that a similar drug is being developed by a competitor that demonstrates greater efficacy or a better safety profile.

The Group’s low cost base ensures that funds are used in the most efficient way.
We undertake extensive early research and create a dossier of information that enables us and our advisers to evaluate the potential of a candidate before we seek to progress to preclinical or clinical phases.
We also seek collaboration partners whose own due diligence reaffirms our assessment of a candidate’s potential.
We collaborate closely with our partners to anticipate and plan around any likely delays.
Collaboration contracts clearly outline responsibilities and key milestones as well as cost, licensing, and revenue sharing.
The management and advisory boards gather as much information as possible on competitive products and programmes.
Progress and key milestones are monitored to understand how these may affect our own programmes.
Sareum also pursues more than one development programme in order to mitigate the overall risk to the Group.